10 Industrials Stocks Moving In Monday’s Pre-Market Session

Gainers Dragonfly Energy Hldgs (NASDAQ:DFLI) stock moved upwards by 35.9% to $5.83 during Monday’s pre-market session. The market…

Gainers

  • Dragonfly Energy Hldgs (NASDAQ:DFLI) stock moved upwards by 35.9% to $5.83 during Monday’s pre-market session. The market value of their outstanding shares is at $252.2 million.
  • Momentus (NASDAQ:MNTS) stock increased by 7.41% to $0.47. The market value of their outstanding shares is at $44.4 million.
  • Atlis Motor Vehicles (NASDAQ:AMV) shares increased by 7.2% to $0.67. The company’s market cap stands at $20.4 million.
  • Markforged Holding (NYSE:MKFG) shares increased by 6.91% to $0.84. The market value of their outstanding shares is at $164.3 million.
  • 1847 Holdings (AMEX:EFSH) stock increased by 6.66% to $0.72. The market value of their outstanding shares is at $3.3 million.
  • Broadwind (NASDAQ:BWEN) stock increased by 6.36% to $4.18. The company’s market cap stands at $87.4 million.

Losers

  • Laser Photonics (NASDAQ:LASE) stock declined by 4.9% to $3.9 during Monday’s pre-market session. The company’s market cap stands at $30.8 million. As per the press release, Q4 earnings came out today.
  • Molekule Group (NASDAQ:MKUL) stock fell 4.71% to $1.62. The company’s market cap stands at $49.2 million.
  • Guardforce AI Co (NASDAQ:GFAI) stock fell 4.68% to $22.25. The company’s market cap stands at $36.0 million.
  • Nuvve Holding (NASDAQ:NVVE) stock fell 4.41% to $0.69. The market value of their outstanding shares is at $17.2 million.
    See Also: www.benzinga.com/money/best-industrials-stocks/

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Why Palisade Bio Stock Is Soaring Today

Palisade Bio shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108. Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.

PALI